Search

Your search keyword '"Di Toritto, Tommaso Caravita"' showing total 10 results
Start Over Author "Di Toritto, Tommaso Caravita"
10 results on '"Di Toritto, Tommaso Caravita"'

1. Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group

Author

Pepe, Sara, Rossi, Elena, Trawinska, Malgorzata, Tatarelli, Caterina, Di Veroli, Ambra, Maurillo, Luca, Romano, Atelda, Crescenzi, Sabrina Leonetti, di Toritto, Tommaso Caravita, Tafuri, Agostino, Latagliata, Roberto, Scalzulli, Emilia, Andriani, Alessandro, De Stefano, Valerio, and Breccia, Massimo

Published
2022
Full Text
View/download PDF

2. Severe chronic primary neutropenia: findings from a patient who underwent exstensive evaluation including adenosine deaminase 2 gene variant assessment

Author

Paciaroni, Katia, primary, Sangiorgi, Eugenio, additional, Pulvirenti, Federica, additional, Villiva, Nicoletta, additional, Andrizzi, Cristina, additional, Campagna, Selenia, additional, Tordi, Attilio, additional, Celesti, Francesca, additional, Manna, Raffaele, additional, Gurrieri, Fiorella, additional, Licci, Stefano, additional, and di Toritto, Tommaso Caravita, additional

Published
2023
Full Text
View/download PDF

3. P-149: Prevalence of type 1 Gaucher disease in patients with multiple myeloma: interim analysis of a prospective, multicentre, observational study

Author

Offidani, Massimo, primary, Zizzo, Carmela, additional, Rupoli, Serena, additional, Federici, Irene, additional, Morè, Sonia, additional, Bossi, Alessandra, additional, Manieri, Valentina Maria, additional, Petrucci, Maria Teresa, additional, di Toritto, Tommaso Caravita, additional, Brunori, Marino, additional, Gozzetti, Alessandro, additional, Tordi, Attilio, additional, Fazio, Francesca, additional, Lisi, chiara, additional, Melaccio, Assunta, additional, Ciuffreda, Lucia, additional, Falcone, Antonietta Pia, additional, Fioritoni, Francesca, additional, Gentili, Silvia, additional, Siniscalchi, Agostina, additional, Trastulli, Fabio, additional, Morsia, Erika, additional, Corvatta, Laura, additional, Olivieri, Attilio, additional, and Duro, Giovanni, additional

Published
2022
Full Text
View/download PDF

4. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide

Author

Larocca, Alessandra, Cavallo, Federica, Bringhen, Sara, Di Raimondo, Francesco, Falanga, Anna, Evangelista, Andrea, Cavalli, Maide, Stanevsky, Anfisa, Corradini, Paolo, Pezzatti, Sara, Patriarca, Francesca, Cavo, Michele, Peccatori, Jacopo, Catalano, Lucio, Carella, Angelo Michele, Cafro, Anna Maria, Siniscalchi, Agostina, Crippa, Claudia, Petrucci, Maria Teresa, Yehuda, Dina Ben, Beggiato, Eloise, Di Toritto, Tommaso Caravita, Boccadoro, Mario, Nagler, Arnon, and Palumbo, Antonio

Published
2012
Full Text
View/download PDF

5. Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies

Author

Bringhen, Sara, primary, Mina, Roberto, additional, Petrucci, Maria Teresa, additional, Gaidano, Gianluca, additional, Ballanti, Stelvio, additional, Musto, Pellegrino, additional, Offidani, Massimo, additional, Spada, Stefano, additional, Benevolo, Giulia, additional, Ponticelli, Elena, additional, Galieni, Piero, additional, Cavo, Michele, additional, Di Toritto, Tommaso Caravita, additional, Di Raimondo, Francesco, additional, Montefusco, Vittorio, additional, Palumbo, Antonio, additional, Boccadoro, Mario, additional, and Larocca, Alessandra, additional

Published
2019
Full Text
View/download PDF

6. Impact of Treatment Intensification According to Patient Prognosis: A Pooled Analysis of 3 Randomized Phase III Trials

Author

D'Agostino, Mattia, primary, Spencer, Andrew, additional, Musto, Pellegrino, additional, Bringhen, Sara, additional, Angelucci, Emanuele, additional, Ciceri, Fabio, additional, Catalano, Lucio, additional, Salvini, Marco, additional, Baraldi, Anna, additional, Grandi, Sonia, additional, Rambaldi, Alessandro, additional, Bosi, Alberto, additional, Vincelli, Iolanda Donatella, additional, Omedè, Paola, additional, Grasso, Mariella, additional, Marasca, Roberto, additional, Cantonetti, Maria, additional, Bernardini, Annalisa, additional, Cascavilla, Nicola, additional, Patriarca, Francesca, additional, Troia, Rossella, additional, Ria, Roberto, additional, Liberati, Anna Marina, additional, Larocca, Alessandra, additional, di Toritto, Tommaso Caravita, additional, Hajek, Roman, additional, Palumbo, Antonio, additional, Boccadoro, Mario, additional, and Gay, Francesca, additional

Published
2017
Full Text
View/download PDF

7. Cardio-vascular Toxicity in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients Treated With Carfilzomib, Cyclophosphamide and Dexamethasone: Results From an Integrated Analysis of 3 Phase I/II Trials

Author

Mina, Roberto, primary, Petrucci, Maria Teresa, additional, Giuliani, Nicola, additional, Carella, Angelo Michele, additional, Genuardi, Mariella, additional, di Toritto, Tommaso Caravita, additional, Ponticelli, Elena, additional, Musto, Pellegrino, additional, Ria, Roberto, additional, Ciccone, Giovannino, additional, Saraci, Elona, additional, Offidani, Massimo, additional, Musolino, Caterina, additional, Troia, Rossella, additional, Liberati, Anna Marina, additional, De Paoli, Lorenzo, additional, Ballanti, Stelvio, additional, Esma, Fabrizio, additional, Galieni, Piero, additional, Cavo, Michele, additional, Conticello, Concetta, additional, Zambello, Renato, additional, Corradini, Paolo, additional, Pregno, Patrizia, additional, Palumbo, Antonio, additional, Sonneveld, Pieter, additional, Boccadoro, Mario, additional, and Bringhen, Sara, additional

Published
2017
Full Text
View/download PDF

8. Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study

Author

Palumbo, Antonio, primary, Cavallo, Federica, additional, Hardan, Izhar, additional, Lupo, Barbara, additional, Redoglia, Valter, additional, Levin, Moshe, additional, Corradini, Paolo, additional, Pezzatti, Sara, additional, Patriarca, Francesca, additional, Cavo, Michele, additional, Marcatti, Magda, additional, Pescosta, Norbert, additional, Falcone, Antonietta Pia, additional, Ria, Roberto, additional, Rossi, Davide, additional, Benevolo, Giulia, additional, Cangialosi, Clotilde, additional, Galli, Monica, additional, Catalano, Lucio, additional, Baraldi, Anna, additional, Carella, Angelo Michele, additional, Cafro, Annamaria, additional, Siniscalchi, Agostina, additional, Crippa, Claudia, additional, Grammatico, Sara, additional, Cavalli, Maide, additional, Di Toritto, Tommaso Caravita, additional, Di Raimondo, Francesco, additional, Nagler, Arnon, additional, and Boccadoro, Mario, additional

Published
2011
Full Text
View/download PDF

9. Onset and Progression of Precancerous Lesions on Gastric Mucosa of Patients Treated for Gastric Lymphoma.

Author

Zullo, Angelo, Rago, Angela, Felici, Stefano, Licci, Stefano, Ridola, Lorenzo, and di Toritto, Tommaso Caravita

Subjects
*PRECANCEROUS conditions, *GASTRIC mucosa, *MUCOSA-associated lymphoid tissue lymphoma, *LYMPHOMAS, *LYMPHOID tissue, *BARRETT'S esophagus, *STOMACH cancer
Abstract

Background & Aims: Patients with primary gastric lymphoma are at an increased risk of developing gastric cancer. Data on gastric precancerous lesions development in these patients are scanty. We assessed gastric precancerous lesions in a cohort of patients with primary lymphoma. Methods: Data of patients with primary gastric lymphoma [mucosa-associated lymphoid tissue (MALT)- lymphoma or diffuse large B-cell lymphoma (DLBCL)] were analysed. Multiple (>10) biopsies were performed on gastric mucosa at each endoscopic control, beyond macroscopic lesions. Presence and distribution of intestinal metaplasia (IM) at baseline, the onset at follow-up, and progression through the stomach or transformation in the incomplete IM type were assessed. The onset of neoplastic lesions was recorded. Results: Data of 50 patients (mean age of 63.6 ± 10.7 years; M/F: 25/25), including 40 with MALT-lymphoma and 10 with DLBCL, with median follow-up of 30.5 months (range: 9-108) and a median of 6 endoscopic controls (range: 3-14) were evaluated. At entry, IM was present in 12 (24%), and it developed in other 22 (57.9%) patients at a median follow-up of 6 (range: 3-40) months. Overall, progression of IM was observed in 7 (21.2%) cases, including extension in the stomach (n=5) or transformation into the incomplete type (n=2). Low-grade dysplasia was detected in 4, and indefinite dysplasia in other 7 patients. In one patient, low-grade dysplasia had progressed to high-grade and gastric adenocarcinoma of the fundus. Conclusions: Our data found a frequent onset and rapid progression of precancerous lesions on gastric mucosa of lymphoma patients. This observation could explain the increased incidence of metachronous gastric cancer in these patients. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

10. Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies

Author

Maria Teresa Petrucci, Mario Boccadoro, Roberto Mina, Massimo Offidani, Pellegrino Musto, Vittorio Montefusco, Stefano Spada, Elena Ponticelli, Giulia Benevolo, Piero Galieni, Antonio Palumbo, Gianluca Gaidano, Michele Cavo, Sara Bringhen, Tommaso Caravita di Toritto, Francesco Di Raimondo, Stelvio Ballanti, Alessandra Larocca, Bringhen, Sara, Mina, Roberto, Petrucci, Maria Teresa, Gaidano, Gianluca, Ballanti, Stelvio, Musto, Pellegrino, Offidani, Massimo, Spada, Stefano, Benevolo, Giulia, Ponticelli, Elena, Galieni, Piero, Cavo, Michele, Di Toritto, Tommaso Caravita, Di Raimondo, Francesco, Montefusco, Vittorio, Palumbo, Antonio, Boccadoro, Mario, and Larocca, Alessandra

Subjects
Male, medicine.medical_specialty, Cyclophosphamide, Antineoplastic Agents, carfilzomib,multiple myeloma, Gastroenterology, Article, Plasma Cell Disorders, Drug Administration Schedule, Maintenance Chemotherapy, chemistry.chemical_compound, Maintenance therapy, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Medicine, Humans, Adverse effect, Survival analysis, Multiple myeloma, Dexamethasone, Aged, Aged, 80 and over, business.industry, Induction chemotherapy, Hematology, Induction Chemotherapy, Middle Aged, medicine.disease, Prognosis, Carfilzomib, Survival Analysis, Treatment Outcome, chemistry, Female, business, Multiple Myeloma, Oligopeptides, medicine.drug
Abstract

Twice-weekly carfilzomib is approved at 27 and 56 mg/m(2) to treat relapsed multiple myeloma patients. In the phase III study ARROW, once-weekly 70 mg/m 2 carfilzomib prolonged the median progression-free survival of relapsed multiple myeloma patients in comparison with twice-weekly 27 mg/m(2) carfilzomib, without adding significant toxicity. Data were pooled from two phase I/II studies of newly diagnosed multiple myeloma patients who received nine induction cycles of carfilzomib (either 70 mg/m(2) once-weekly or 36 mg/m(2) twice-weekly), cyclophosphamide and dexamethasone, followed by carfilzomib maintenance. Overall, 121 transplant-ineligible patients with newly diagnosed multiple myeloma were analyzed (once-weekly, n=63; twice-weekly, n=58). We found no significant difference in median progression-free survival [35.7 months (95%CI: 23.7-not reached, NR) vs 35.5 months (95%CI: 24.3-NR); HR: 1.39; P=0.26] and 3-year overall survival [70% [95%CI: 59%-84%) vs 72% (95%CI: 60%-85%); HR: 1.27; P=0.5] between once-weekly and twice-weekly carfilzomib. From the start of maintenance, 3-year progression-free survival [47% (95%CI: 33%-68%) vs 51% (95%CI: 38%-70%); HR: 1.04; P=0.92] and overall survival [72% (95%CI: 58%-89%) vs 73% (95%CI: 59%-90%); HR: 0.82; P=0.71] were similar in the once- versus twice-weekly carfilzomib. The rate of grade 3-5 hematologic (24% vs 30%; P=0.82) and non-hematologic (38% vs 41%; P=0.83) adverse events was similar in the two groups. Once-weekly 70 mg/m(2) carfilzomib as induction and maintenance therapy for newly diagnosed multiple myeloma patients was as safe and effective as twice-weekly 36 mg/m(2) carfilzomib and provided a more convenient schedule. The trials are registered at clinicaltrials.gov identifiers: 01857115 (IST-CAR-561) and 01346787 (IST-CAR-506).

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results